Competing risk estimations and Landmark analyses were applied when indicated. Blood ; 22 : Induction of chronic myelogenous leukemia: current status and investigational options. Treatment was continued until disease progression, death, intolerance to imatinib or allogeneic stem cell transplantation SCT. Please try after some time. You may be trying to access this site from a secured browser on the server. Content Menu.
Gianantonio Rosti, MD. Rosti:BMS: Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or.
Document Nilotinib a viewpoint by Gianantonio Rosti
Background: Successful tyrosine-kinase inhibitors (TKIs) discontinuation has been obtained in some patients (pts) with chronic-phase chronic.
Joerg Hasford, Gianantonio Rosti, Doris Lindoerfer, Michele Baccarani, Joelle Guilhot, Lara Montrucchio, Your email address, e.g. [email protected]
J Clin Oncol. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Our results show that a stable and confirmed CCgR to a tyrosine kinase inhibitor treatment policy, even when the disease has progressed to AP, constitutes an affordable surrogate marker of long-term overall and event-free survival.
The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. Date: Jan. Journal List Haematologica v.
Corresponding author; email: @ Fabio Efficace, Gianantonio Rosti, Neil Aaronson, Francesco Cottone, Emanuele Angelucci, Stefano Molica, Marco Vignetti, Franco Mandelli, Michele Baccarani.
Document In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Gianantonio Rosti: speaker bureau for Novartis, Bristol-Myers Squibb, Pfizer e Incyte. Gianantonio Rosti, Email: @anaig.
Thanks for registering! Progression-free survival was calculated from first imatinib intake to progression to blast crisis, death from any cause or last follow-up. In multivariate analysis, a Performance Status lower than 2 was the only independent prognostic factor for better survival.
No additional serious safety concerns were identified with longer term follow-up, and no treatment-related deaths occurred.
Wp facet zdrowie i natura
|J Am Stat Assoc.
Thanks for registering! Best hematologic and cytogenetic responses according to previous treatment and to age at starting imatinib. Latest Issue Alert. Figure 2.
Video: Gianantonio rosti email inbox The state of your email inbox